Passions

Adventure Travel
(I just climbed Mt. Kilimanjaro)

Fashion

Volunteer Work

Experience

Alto Neuroscience – $75 Million Debt Financing

January 13, 2025

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its up to $75 million debt financing. Partner Addison Pierce led the Cooley team, which included Courtney Tygesson, Madison Jones, Margaret Barreto and Katie Lapidus.

Related contacts

Addison Pierce
Partner, Chicago
Courtney M.W. Tygesson
Partner, Chicago
Madison Jones
Partner, Washington, DC
Margaret Barreto
Associate, San Francisco
Katie Lapidus
Associate, Washington, DC

PhaseBio Chapter 11 Wind-Down Plan Goes Effective

June 26, 2024

The Chapter 11 plan of PhaseBio Pharmaceuticals, a long-standing Cooley life sciences client, has gone effective following the court’s confirmation of the Chapter 11 plan on June 26, 2024. The plan provides for a global settlement with the official committee of unsecured creditors and a settlement with PhaseBio’s former co-development partner. The Chapter 11 bankruptcy case in the US Bankruptcy Court for the District of Delaware was handled by a multioffice, cross-disciplinary Cooley team.

Related contacts

Jeremiah P. Ledwidge
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Olya Antle
Associate, Washington, DC
Cullen Drescher Speckhart
Partner in Charge – Washington, DC, Washington, DC
Philip Bowman
Partner, New York
Victoria R. Pasculli
Associate, New York
Daniel Lockaby
Associate, New York
Dannielle Antone
Associate, San Francisco
Aaron Binstock
Partner, Washington, DC
Amanda Lindner
Associate, New York
Madison Jones
Partner, Washington, DC
Timothy Shapiro
Partner, Palo Alto
Grigor Lynch
Associate, Colorado
Christian Plaza
Partner, Reston
Joe Sandys
Special Counsel, London
Aaron Pomeroy
Partner, Colorado
David Brinton
Associate, Washington, DC
Paul Springer
Associate, New York
Erika Freeman
Associate, New York
Michael Klein
Partner, New York
Daniel Knauss
Partner, Palo Alto
Pengli Li
Associate, Boston
Marya Postner
Partner, Palo Alto
Leo Metz
Associate
Dr. Michael Tuscan
Partner, Washington, DC
Allison Wettstein O’Neill
Associate, San Diego

Related Practices & Industries

Zoetis – $1.35 Billion Investment Grade Bond Offering

November 8, 2022

Cooley advised Zoetis on its $1.35 billion aggregate principal amount of investment-grade unsecured senior notes, $600 million of 5.400% senior notes due 2025, and $750 million of 5.600% senior notes due 2032. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. Eric Blanchard and Madison Jones led the Cooley team.

Related contacts

Eric Blanchard
Partner, Boston
Madison Jones
Partner, Washington, DC
Katherine Denby
Special Counsel, Washington, DC
Olivia Creser
Associate, New York

Related Practices & Industries

Scholar Rock – $205 Million Registered Direct Offering

June 18, 2022

Cooley advised the placement agents in Scholar Rock’s $205 million registered direct offering, with J.P. Morgan as lead placement agent and Piper Sandler as co-placement agent . Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Partners Daniel Goldberg, Div Gupta and Madison Jones led the Cooley team.

Related contacts

Daniel I. Goldberg
Partner, New York
Div Gupta
Partner, New York
Madison Jones
Partner, Washington, DC
Darah Protas
Partner, Washington, DC
Olivia Creser
Associate, New York

Related Practices & Industries

MaxCyte – $202 Million IPO

July 30, 2021

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Related contacts

Christian Plaza
Partner, Reston
Brian Leaf
Partner, Reston
Claire Keast-Butler
Co-Partner in Charge – London, London
Katie Kazem
Partner, Reston
Paul Alexander
Associate, Washington, DC
Div Gupta
Partner, New York
Madison Jones
Partner, Washington, DC
Denny Xu
Associate, Boston

Related Practices & Industries

View more

Admissions and credentials

District of Columbia